Analyst Proposes $465 Target, Stryker Unveils Triathlon Gold Implants and Mako Upgrades
An analyst sets a $465 price target for Stryker, implying 21.76% upside from its current near-$382 level. The company introduced Triathlon Gold and Medial Stabilized knee implants and expanded its Mako SmartRobotics platform with new shoulder and power tool offerings.
1. Analyst Price Target
A Jefferies analyst set a $465 price target for Stryker, reflecting a projected 21.76% increase from its current trading price near $382. This Buy rating underscores confidence in Stryker’s growth trajectory and positions the company above its recent trading range of $380.87–$384.51.
2. New Orthopedic Implants
At the American Academy of Orthopedic Surgeons’ 2026 Annual Meeting, Stryker unveiled its Triathlon Gold and Medial Stabilized knee implant systems. These products aim to enhance joint stability and address metal sensitivity, reinforcing Stryker’s leadership in advanced orthopedic solutions.
3. Robotics Platform Expansion
Stryker expanded its Mako SmartRobotics offerings with the launch of Mako Shoulder, as well as RPS, BPX and TPX HD power tools. These enhancements are designed to broaden the company’s minimally invasive surgical suite and drive long-term adoption of its technology-driven orthopedic portfolio.